Sources last read 2026-08-23

The research desk

Original answers. The rows are attached.

We read public drug, trial, safety and price records to answer questions the source files do not answer on their own. Every report keeps the query, retrieval date, limits and reusable table beside the finding.

Current ledger

Reports: 9
Datasets: 11
Committed rows: 4,834 rows
Upstream sources: 9

Latest source read 2026-08-23. No live counter and no deploy-date freshness.

Featured analysis

A finding built to be checked

9 published rows

Safety and use

Dose-handling reports across GLP-1 product forms

Which product forms appear most often in dose-handling reports?

For nine drugs, this table shows the share of FDA side-effect reports that name a dose-handling term. Each share sits beside the product form. Counts of reports, not rates.

Rows: 9
Read: 2026-08-17
Edition: 2026.08
Version: 4ccde919bfa3

Read the report and inspect the data →

The full ledger

Research by question

Each card returns to the canonical report. Downloads and reference-manager files live there, so one URL owns the answer and one version owns the table.

Clinical development

The registered peptide and GLP-1 trial pipeline

Which compounds have registered human trials, and how far have they reached?

For every compound on this site, this table counts registered studies and the ones still recruiting. It also shows the highest phase and next main-measurement date. Compounds with no registered study are rows too.

Rows: 36
Read: 2026-08-23
Edition: 2026.08
Version: 198288fe6fa4

A year-by-year count of active, identity-checked registered studies whose sponsor-filed primary-completion date had not passed when the registry was read. Multi-compound studies count once in the study total and once per compound in the association total.

Rows: 6
Read: 2026-08-23
Edition: 2026.08
Version: 6adf12340e8d

Read the report and inspect the data →

Clinical development

Recruiting peptide and GLP-1 study locations

Where do sponsors currently list recruiting study locations?

Sponsor-registered study locations for identity-checked peptide and GLP-1 trials, grouped by NCT record and exact place while preserving repeated rows and conflicting site statuses.

Rows: 3,696
Read: 2026-08-23
Edition: 2026.08
Version: 91ffc6bcafe5

Read the report and inspect the data →

Clinical development

Registered human trials of peptide delivery through skin

What has actually been tested through the skin in people?

For every molecule, this table counts registered trials of delivery through skin. It shows the furthest phase, posted results and molecular weight. Molecules with no registered study are rows too.

Rows: 6
Read: 2026-08-12
Edition: 2026.08
Version: bcb8762b13b6

Read the report and inspect the data →

Access and regulation

What named GLP-1 patch listings disclose

What do named patch listings say is in the product?

Ten named products sold as GLP-1 patches, grouped by product type. Each row shows the ingredients, drug claim, disclaimer, price and date read that the listing publishes or omits.

Rows: 10
Read: 2026-08-13
Edition: 2026.08
Version: a90242aebb3c

Read the report and inspect the data →

Access and regulation

FDA warning letters naming peptide and GLP-1 sellers

Which sellers and claims appear in FDA warning letters?

Every FDA warning letter in the naming window that mentions a tracked GLP-1 drug or peptide. Each row keeps FDA’s subject line, both dates and close-out status.

Rows: 150
Read: 2026-08-12
Edition: 2026.08
Version: f72779015267

Read the report and inspect the data →

Cost and supply

Federal listings and recalls across the peptide supply chain

What appears in federal drug listings and recall records?

Every listing FDA’s National Drug Code directory holds for these compounds. Each row shows the labeler, marketing category and FDA’s flag for a finished medicine or raw ingredient.

Rows: 577
Read: 2026-08-17
Edition: 2026.08
Version: 378fefb14c5f

Every recall record FDA’s enforcement database holds for these compounds. Each row shows the hazard class, process status, recalling firm and FDA’s stated reason.

Rows: 296
Read: 2026-08-17
Edition: 2026.08
Version: 33d460f14b0e

Read the report and inspect the data →

Cost and supply

FDA shortage status for GLP-1 drugs

What does FDA currently list as in shortage?

Whether FDA’s drug shortage database lists semaglutide or tirzepatide as in shortage on the date read. Current, closed and discontinued records are counted separately. A drug with no record is a row too.

Rows: 2
Read: 2026-08-14
Edition: 2026.08
Version: c8b4cf25d815

Read the report and inspect the data →

Cost and supply

The federal pharmacy acquisition benchmark for GLP-1 drugs

What does a pharmacy acquisition benchmark show beneath retail prices?

The national average drug acquisition cost CMS publishes for each GLP-1 product. Each row works the pricing unit through to a package and a month, with the date it took effect.

Rows: 46
Read: 2026-08-13
Edition: 2026.08
Version: 68bddefe4742

Read the report and inspect the data →

Reuse the work

Citable by design, not by decoration

The analysis tables are published under CC BY 4.0. CSV and JSON preserve the rows; BibTeX and RIS preserve the title, edition, version, retrieval date and canonical URL. A source manifest records provenance, limits, rights and exact file hashes. Source rights and our arrangement license are stated separately on every report.

Read the method